ICM
CORT icon

Islay Capital Management’s Corcept Therapeutics CORT Stock Holding History

Islay Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,320
Closed -$111K – 259
2020
Q1 		$111K Buy
+9,320
New +$115K 0.15% 83

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Islay Capital Management's CORT Position: Q2 2020 in Review

Islay Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2020, closing a stake of 9,320 shares — an estimated $111K sold.

Islay Capital Management first reported a position in CORT in Q1 2020 and held it in 1 quarter. The position peaked at $111K in Q1 2020. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2020.

  • Islay Capital Management reported no remaining Corcept Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Islay Capital Management sold 9,320 Corcept Therapeutics shares in Q2 2020, an estimated $111K.
  • Islay Capital Management first reported a position in Corcept Therapeutics in Q1 2020 and held it in 1 quarter.
  • Islay Capital Management's Corcept Therapeutics position peaked at $111K in Q1 2020.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2020.

Based on Islay Capital Management's 13F filing for Q2 2020, filed 4 Aug 2020.